CO6270227A2 - Derivados de quinazolinadiona su preparacion y sus aplicaciones terapeuticas - Google Patents

Derivados de quinazolinadiona su preparacion y sus aplicaciones terapeuticas

Info

Publication number
CO6270227A2
CO6270227A2 CO10036551A CO10036551A CO6270227A2 CO 6270227 A2 CO6270227 A2 CO 6270227A2 CO 10036551 A CO10036551 A CO 10036551A CO 10036551 A CO10036551 A CO 10036551A CO 6270227 A2 CO6270227 A2 CO 6270227A2
Authority
CO
Colombia
Prior art keywords
group
alkyl
optionally substituted
aryl
hydrogen atom
Prior art date
Application number
CO10036551A
Other languages
English (en)
Inventor
Annie Clauss
Christophe Glaess
Bertrand Vivet
Andre Seyer
Jean-Francois Nave
Nicolas Muzet
Gilbert Marciniak
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO6270227A2 publication Critical patent/CO6270227A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

1.- Compuesto que responde a la formula general (I):en la que - A representa un grupo arilo o un grupo heteroarilo; - R1 representa: ° un atomo de hidrogeno, ° -C(O)R en el que R es un atomo de hidrogeno, un grupo alcoxi (C1-C6), un grupo arilo, un grupo cicloalquilo(C3-C6), o un grupo alquilo(C1-C6), estando dicho alquilo sustituido opcionalmente con:. uno o varios grupo(s) hidroxi, . un grupo benciloxi, . un grupo alcoxi(C1-C6), opcionalmente sustituido con un arilo, o. un grupo cicloalquilo (C3-C6), ° un grupo alquilo(C1-C6), opcionalmente sustituido - R2 representa: ° un atomo de hidrogeno, ° un atomo de halogeno, ° un grupo ciano, ° un grupo nitro, ° un grupo alquilo (C1-C6) sustituido opcionalmente con un -NH2, o bien con un grupo -NHC(O)Rb, ° un grupo -ORa en el que Ra representa: . un atomo de hidrogeno, . un grupo alquilo(C1-C6) opcionalmente sustituido con uno o varios atomo(s) de halogeno, con uno o varios grupo(s) hidroxi, con un grupo arilo y/o con uno o varios grupo(s) ciano, . un grupo alquinilo (C2-C6); ° un grupo arilo; - R3 representa: ° un atomo de hidrogeno, ° un atomo de halogeno, ° un grupo hidroxi, ° un grupo ciano, ° un grupo -SCF3, ° un grupo nitro, ° un grupo oxo, ° un grupo -S(O)0-2-alquilo, un grupo -S(O)0-2- heterocicloalquilo, un grupo -O- SO2-arilo opcionalmente sustituido con uno o varios atomo(s) de halogeno; ° un grupo -alquil-amino-alquilo o -cicloalquil-amino-alquilo, cada uno opcionalmente sustituido en el alquilo terminal, ...
CO10036551A 2007-10-03 2010-03-26 Derivados de quinazolinadiona su preparacion y sus aplicaciones terapeuticas CO6270227A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706931A FR2921926B1 (fr) 2007-10-03 2007-10-03 Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.

Publications (1)

Publication Number Publication Date
CO6270227A2 true CO6270227A2 (es) 2011-04-20

Family

ID=39470387

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10036551A CO6270227A2 (es) 2007-10-03 2010-03-26 Derivados de quinazolinadiona su preparacion y sus aplicaciones terapeuticas

Country Status (40)

Country Link
US (1) US8242126B2 (es)
EP (1) EP2205593B1 (es)
JP (1) JP5411143B2 (es)
KR (1) KR20100082345A (es)
CN (1) CN101842368B (es)
AR (1) AR070655A1 (es)
AU (1) AU2008337382B2 (es)
BR (1) BRPI0818690A2 (es)
CA (1) CA2701150C (es)
CL (1) CL2008002946A1 (es)
CO (1) CO6270227A2 (es)
CR (1) CR11327A (es)
CY (1) CY1117461T1 (es)
DK (1) DK2205593T3 (es)
DO (1) DOP2010000089A (es)
EA (1) EA018766B1 (es)
EC (1) ECSP10010058A (es)
ES (1) ES2567567T3 (es)
FR (1) FR2921926B1 (es)
GT (1) GT201000069A (es)
HN (1) HN2010000572A (es)
HR (1) HRP20160359T1 (es)
HU (1) HUE028770T2 (es)
IL (1) IL204814A0 (es)
MA (1) MA31832B1 (es)
MX (1) MX2010003495A (es)
MY (1) MY153763A (es)
NI (1) NI201000039A (es)
NZ (1) NZ584430A (es)
PA (1) PA8797701A1 (es)
PE (1) PE20090960A1 (es)
PL (1) PL2205593T3 (es)
SI (1) SI2205593T1 (es)
SV (1) SV2010003514A (es)
TN (1) TN2010000130A1 (es)
TW (1) TWI421076B (es)
UA (1) UA99485C2 (es)
UY (1) UY31376A1 (es)
WO (1) WO2009077680A1 (es)
ZA (1) ZA201002307B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8107260B2 (en) * 2007-11-15 2012-01-31 Illinois Tool Works Inc. EMI shielding and environmental seal device
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
FR2944206B1 (fr) * 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
KR101116234B1 (ko) * 2009-10-29 2014-03-06 (주)퓨쳐켐 (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
EP2576536B1 (en) * 2010-06-01 2016-09-14 The University of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
BR112014026305A2 (pt) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
JP6177768B2 (ja) 2012-04-24 2017-08-09 中外製薬株式会社 ベンズアミド誘導体
WO2013184806A1 (en) 2012-06-05 2013-12-12 University Of Kansas Inhibitors of respiratory syncytial virus
WO2015003879A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicylic derivatives
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
CZ2015601A3 (cs) * 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CN107267455A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种嵌合抗原受体nk细胞的制备方法
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
EP0825993A1 (en) * 1995-05-19 1998-03-04 Chiroscience Limited Xanthines and their therapeutic use
JP2002308774A (ja) * 2001-04-12 2002-10-23 Nippon Zoki Pharmaceut Co Ltd Ｉｖ型ホスホジエステラーゼ選択的阻害剤
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AU2006219643A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of PDE7 inhibitors for the treatment of neuropathic pain
WO2007067946A2 (en) 2005-12-07 2007-06-14 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (cll)

Also Published As

Publication number Publication date
FR2921926B1 (fr) 2009-12-04
DK2205593T3 (en) 2016-04-18
EA201070424A1 (ru) 2011-04-29
CY1117461T1 (el) 2017-04-26
NZ584430A (en) 2011-11-25
US8242126B2 (en) 2012-08-14
KR20100082345A (ko) 2010-07-16
PE20090960A1 (es) 2009-08-10
FR2921926A1 (fr) 2009-04-10
AU2008337382A1 (en) 2009-06-25
TN2010000130A1 (fr) 2011-09-26
PA8797701A1 (es) 2009-05-15
MA31832B1 (fr) 2010-11-01
MY153763A (en) 2015-03-13
EA018766B1 (ru) 2013-10-30
ZA201002307B (en) 2011-06-29
TW200922591A (en) 2009-06-01
WO2009077680A1 (fr) 2009-06-25
PL2205593T3 (pl) 2016-09-30
HUE028770T2 (en) 2016-12-28
DOP2010000089A (es) 2010-05-15
NI201000039A (es) 2010-08-13
TWI421076B (zh) 2014-01-01
CL2008002946A1 (es) 2010-02-12
CR11327A (es) 2010-09-13
JP5411143B2 (ja) 2014-02-12
HRP20160359T1 (hr) 2016-05-06
UY31376A1 (es) 2009-05-29
BRPI0818690A2 (pt) 2015-04-14
MX2010003495A (es) 2010-04-21
CN101842368B (zh) 2014-03-12
IL204814A0 (en) 2010-11-30
EP2205593B1 (fr) 2016-01-13
AU2008337382B2 (en) 2013-11-21
SI2205593T1 (sl) 2016-05-31
AR070655A1 (es) 2010-04-28
CN101842368A (zh) 2010-09-22
JP2010540602A (ja) 2010-12-24
US20100298298A1 (en) 2010-11-25
GT201000069A (es) 2012-03-26
CA2701150C (fr) 2016-08-16
EP2205593A1 (fr) 2010-07-14
CA2701150A1 (fr) 2009-06-25
ECSP10010058A (es) 2010-04-30
ES2567567T3 (es) 2016-04-25
SV2010003514A (es) 2011-01-31
UA99485C2 (ru) 2012-08-27
HN2010000572A (es) 2013-03-11

Similar Documents

Publication Publication Date Title
CO6270227A2 (es) Derivados de quinazolinadiona su preparacion y sus aplicaciones terapeuticas
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
DOP2010000396A (es) Derivado de uracilo o timina para el tratamiento de hepatitis c
CO6020004A1 (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
NO20091141L (no) Pyrido (2,3-D) pyrimidinonforbindelser og deres anvendelse som P13 inhibitorer
ECSP12011867A (es) Derivados bencimidazol-imidazol
DK1888614T3 (da) Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
AR066104A1 (es) Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica
NO20090596L (no) Antivirale fosfinatforbindelser
UY31065A1 (es) Heterociclos ciclicos
AR060590A1 (es) Compuestos imidazo
UY30105A1 (es) Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas.
AR069531A1 (es) Derivados de indolinona y procedimiento para su fabricacion
PA8795301A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
ECSP088194A (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
AR064415A1 (es) Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
CO6571898A2 (es) Composición pesticida y su uso

Legal Events

Date Code Title Description
FG Application granted